Posted by MarketBeat News on Jun 28th, 2024
Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) fell 4% during mid-day trading on Wednesday . The company traded as low as $15.76 and last traded at $15.77. 48,316 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 679,383 shares. The stock had previously closed at $16.42.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on the company. Wedbush reissued an “outperform” rating and set a $36.00 price target on shares of Cullinan Therapeutics in a report on Thursday, May 16th. Jonestrading lifted their target price on Cullinan Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. BTIG Research upped their price target on Cullinan Therapeutics from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. William Blair reiterated an “outperform” rating on shares of Cullinan Therapeutics in a research report on Monday, June 3rd. Finally, HC Wainwright restated a “buy” rating and set a $28.00 target price on shares of Cullinan Therapeutics in a research report on Monday, June 3rd. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cullinan Therapeutics presently has an average rating of “Buy” and a consensus target price of $32.00.
Get Our Latest Research Report on CGEM
Cullinan Therapeutics Trading Up 3.6 %
The business has a 50-day moving average price of $22.49 and a 200 day moving average price of $17.36. The stock has a market capitalization of $984.90 million, a P/E ratio of -5.46 and a beta of -0.06.
Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.04. On average, sell-side analysts predict that Cullinan Therapeutics, Inc. will post -3.02 earnings per share for the current fiscal year.
Insider Transactions at Cullinan Therapeutics
In related news, insider Jennifer Michaelson sold 58,000 shares of Cullinan Therapeutics stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $28.07, for a total transaction of $1,628,060.00. Following the completion of the sale, the insider now owns 129,582 shares in the company, valued at approximately $3,637,366.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 6.07% of the company’s stock.
Institutional Investors Weigh In On Cullinan Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the company. Trexquant Investment LP bought a new position in shares of Cullinan Therapeutics during the 4th quarter worth $356,000. Parkman Healthcare Partners LLC raised its holdings in shares of Cullinan Therapeutics by 20.8% in the fourth quarter. Parkman Healthcare Partners LLC now owns 529,877 shares of the company’s stock valued at $5,399,000 after acquiring an additional 91,132 shares in the last quarter. Citigroup Inc. raised its holdings in shares of Cullinan Therapeutics by 186.1% in the third quarter. Citigroup Inc. now owns 23,534 shares of the company’s stock valued at $213,000 after acquiring an additional 15,308 shares in the last quarter. Schonfeld Strategic Advisors LLC raised its holdings in shares of Cullinan Therapeutics by 15.9% in the third quarter. Schonfeld Strategic Advisors LLC now owns 121,800 shares of the company’s stock valued at $1,102,000 after acquiring an additional 16,700 shares in the last quarter. Finally, Quest Partners LLC bought a new stake in shares of Cullinan Therapeutics in the fourth quarter valued at about $179,000. 86.31% of the stock is owned by institutional investors.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Read More
- Five stocks we like better than Cullinan Therapeutics
- What is the FTSE 100 index?
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- Using the MarketBeat Dividend Tax Calculator
- Progress Software Stock Back in the Green After Beating Forecasts
- 3 Best Fintech Stocks for a Portfolio Boost
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Cullinan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
You might be interested in:
Congress Wealth Management LLC DE Has $13.07 Million Stock Position in Oracle Co.
Colton Groome Financial Advisors LLC Sells 716 Shares of Invesco QQQ
Steele Capital Management Inc. Increases Position in Invesco QQQ
Tributary Capital Management LLC Lowers Position in Alphabet Inc.